Denise Yardley, MD, is a medical oncologist with Tennessee Oncology, who specializes in breast cancer. Much of her research has focused on HER2 breast cancer, and she has been involved with trials with pretreated patients whose cancer progresses or who don’t achieve a complete response.
Neil M. Iyengar, MD, is a medical oncologist and clinical investigator at Memorial Sloan Kettering, Weill Cornell Medical College and Rockefeller University, who work investigates the links between metabolic health and breast cancer. A key component of his research is the development of clinical trials that examine the role of medication alongside diet and exercise, to prevent obesity-related cancers and improve outcomes.
Sara A. Hurvitz, MD, of UCLA Health spoke with The American Journal of Managed Care® (AJMC®) about advanced hormone receptor–positive (HR+), HER2-negative breast cancer and the emergence of CDK4/6 inhibitors with endocrine therapy as the “gold standard” for first-line treatment.
In a career spanning 45 years, Gabriel N. Hortobagyi, MD, has seen the number of cancer therapies increase from 8-10 for all of oncology to more than 400. Here, he discusses the importance of overall survival in breast cancer as seen in the MONALEESA-2 trial.
Nicholas McAndrew, MD, MSCE, a medical oncologist and breast cancer specialist at UCLA Health and assistant clinical professor of Medicine at UCLA in the Division of Hematology/Oncology, discusses the arrival of CDK4/6 inhibitors in the treatment landscape.
